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ABSTRACT
Background Marked geographical disparities in 
survival from colon cancer have been consistently 
described in England. Similar patterns have been 
observed within London, almost mimicking a microcosm 
of the country’s survival patterns. This evidence has 
suggested that the area of residence plays an important 
role in the survival from cancer.
Methods We analysed the survival from colon cancer 
of patients diagnosed in 2006–2013, in a pre- pandemic 
period, living in London at their diagnosis and received 
care in a London hospital. We examined the patterns of 
patient pathways between the area of residence and the 
hospital of care using flow maps, and we investigated 
whether geographical variations in survival from colon 
cancer are associated with the hospital of care. To 
estimate survival, we applied a Bayesian excess hazard 
model which accounts for the hierarchical structure of 
the data.
Results Geographical disparities in colon cancer 
survival disappeared once controlled for hospitals, 
and the disparities seemed to be augmented between 
hospitals. However, close examination of patient 
pathways revealed that the poorer survival observed 
in some hospitals was mostly associated with higher 
proportions of emergency diagnosis, while their 
performance was generally as expected for patients 
diagnosed through non- emergency routes.
Discussion This study highlights the need to better 
coordinate primary and secondary care sectors in some 
areas of London to improve timely access to specialised 
clinicians and diagnostic tests. This challenge remains 
crucially relevant after the recent successive regroupings 
of Clinical Commissioning Groups (which grouped 
struggling areas together) and the observed exacerbation 
of disparities during the COVID-19 pandemic.
INTRODUCTION
Population- based cancer survival statistics provide 
key insights into the overall effectiveness of a 
healthcare system in managing and treating patients 
with cancer.1 Quantifying disparities in cancer 
survival in particular can directly identify areas of 
inequity amenable to change. For instance, wide 
geographical and socioeconomic inequalities in 
cancer survival have been consistently described, 
despite the existence of universal access to care 
within the National Health Service (NHS), founded 
on the principles of equity and free access to all.2–5 
A clear and persistent North–South gradient, with 
lower survival in the North of England, has been 
observed for most common adult cancer types, with 
similar patterns reported within London, almost 
mimicking a microcosm of the country’s survival 
patterns. This evidence has suggested that the 
place of residence might play an important role in 
the survival of a patient with cancer, giving rise to 
much political debate since the introduction of the 
first NHS cancer plan and other national initiatives 
aimed at tackling cancer inequalities.6–8 Studying 
geographical variations in health outcomes is chal-
lenging as English health geographies have contin-
uously changed over the last decades, through 
mergers, boundary changes, creation and cessation 
of geographies.9 10 Following the 2012 Health and 
Social Care Act and the subsequent restructuring 
of the NHS, two organisations became central role 
players in the organisation and commissioning of 
care: NHS England and Clinical Commissioning 
Groups (CCGs).11 NHS England became respon-
sible for commissioning the planning and buying of 
healthcare services, such as primary care services, 
and setting the priorities and direction of the NHS. 
It also allocates 60% of the NHS budget to CCGs 
across England. CCGs are clinically led statutory 
NHS bodies responsible for the planning and 
commissioning of healthcare services for their local 
area, including general practitioner (GP) services, 
planned hospital, urgent and emergency care. More 
recently, CCGs have been merged, from the initial 
212 to 135 in 2020, and further to 106 from 1 
April 2021. Cancer survival outcomes for CCGs 
have been published on a regular basis since their 
creation, including an index of cancer survival for 
all cancers combined and cancer- specific survival 
indexes for breast, colorectum and lung cancers.12 
These outcomes have provided evidence of wide 
geographical variation in cancer across England, as 
well as within London. Understanding the mech-
anisms underlying such wide disparities requires 
addressing multiple research questions to disen-
tangle the different aspects of the multilayered and 
multifactorial ‘cancer inequalities puzzle’, including 
the integrated study of patient- system, tumour- 
system and health- system characteristics. In this 
article, we examine the geographical variations in 
colon cancer outcomes among patients living in 
London (England) in order to examine whether 
geographical variation in cancer survival is associ-
ated with the hospital of care. We use the catch-
ment area of each CCG (as defined in 2013) as the 
geographical unit of analysis. We start by investi-
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area of residence and the NHS hospital of cancer care. Next, we 
investigate the variability in cancer survival at both CCG and 
hospital level after adjusting for some patient and tumour char-




Data on individual cancer records were obtained from the 
National Cancer Registry at the Office for National Statistics 
for all adults (aged 15–99 years) diagnosed with a first, primary, 
invasive malignancy of the colon during 2006–2013 in London, 
England. All patients were followed up to update their vital 
status until 31 December 2014. The data variables available for 
analysis from this data source were gender, age at diagnosis, 
full dates of diagnosis, last follow- up and death, vital status 
indicator (dead or censored as alive at the end of follow- up), 
CCG of residence at diagnosis, deprivation category (1—least 
deprived to 5—most deprived), colon cancer stage at diagnosis 
(1—localised cancer stage to 4—metastatic cancer stage) and 
routes to diagnosis (screen- detected, 2- week wait, emergency 
presentation, GP referral, inpatient elective, other outpatient, 
death certificate only, unknown).13 14 A CCG of residence was 
allocated to each patient based on his/her postcode of residence. 
Deprivation categories (1—least deprived to 5—most deprived) 
were defined according to the quintiles of the distribution of 
the Income Domain scores of the 2011 Indices of Multiple 
Deprivation (IMD) in all Lower Super Output Areas (LSOA) in 
England. Each patient was then allocated to one of these five 
deprivation categories based on his/her LSOA of residence at the 
time of his/her diagnosis. We selected the Income Domain as 
the ecological measure of deprivation because it tries to quan-
tify material wealth (as opposed to housing, educational or 
health deprivation) and is thus more comparable with measures 
of material deprivation. It has been shown that socioeconomic 
inequalities were well measured using the Income Domain of the 
IMD and were consistent with other commonly used measures 
such as Carstairs.15 To complement the cancer registry dataset 
with information on stage at diagnosis and hospital of cancer 
care, each individual cancer record was linked to two additional 
sources of data, Hospital Episode Statistics (HES) records and 
the National Bowel Cancer Clinical Audit data, using a data 
linkage algorithm by Shack et al.16 After the three data sources 
were linked, the stage at diagnosis variable was reconstructed 
using the algorithm by Benitez Majano et al17 that combines 
available information on tumour (T), nodes (N) and metastases 
(M). The algorithm prioritises information captured in the clin-
ical audit data and, if not available, uses cancer registry stage 
data. Treatment information was also derived from clinical audit 
data and HES records using an algorithm by Fowler et al18 that 
categorises major surgical treatment received by each patient 
within a time window of between 30 days prior and 90 days 
following cancer diagnosis, and categorises other minor forms 
of treatment (including palliative care and diagnostic procedures 
if no other treatment was recorded) into a minor treatment cate-
gory. Based on the previous definition of treatment categories, 
we allocated to each patient with cancer a hospital of cancer 
care, or diagnosis if no major surgical treatment was received, 
using a combination of different variables available in the data 
containing hospital codes.
Statistical methods and data visualisation
In addition to usual descriptive statistics calculated in Stata 
software V.15,19 various data visualisation techniques were 
used. Windrose graphs were used to display the distribution of 
patients’ deprivation category and stage at diagnosis by CCG 
of residence and hospital of cancer care. CCGs and hospitals 
were arranged in the windroses according to their approx-
imate cardinal directions of location in London for ease of 
visualisation. Flow maps of London were created to visualise 
patterns of patient pathways between the CCG of residence 
and the hospital of cancer care. The maps show the areas of 
catchment and boundaries for each of the 32 London CCGs, 
all identified with their names. The 36 London NHS hospi-
tals used in this study are marked on the maps using the exact 
location based on their latitude and longitude coordinates. 
All these hospitals include tertiary referral departments. The 
key to the hospital names is given in the map legend using 
the identifiers (H1, H2, …, H36). Each pathway is shown 
on the map using lines connecting the centroid of each CCG 
(black dot) to each hospital. The pathway line colours distin-
guish between the frequency of each pathway, coloured from 
the most frequent up to the fifth most frequent, with the 
proportion (%) of patients using each pathway indicated on 
the lines. Only pathways that had more than 5% of patients 
were drawn, and thus, the sum of all the pathway frequencies 
originating from each CCG will not add to 100%. Maps were 
created using the software ArcGIS V.10.5.20
In order to investigate the variability in cancer survival 
at CCG and hospital levels, net survival (survival from 
the cancer) and excess hazard of death (hazard due to the 
cancer) were estimated using flexible Bayesian excess hazard 
models proposed by Quaresma et al.21 Separate models were 
fitted for men and women, adjusting for age at diagnosis, 
deprivation category and stage at diagnosis. To accommo-
date the hierarchical structure of the data (ie, that patients 
within a given CCG of residence or hospital of cancer care 
are likely to share some characteristics), the original model 
by Quaresma et al21 was extended with the inclusion of a 
pair of random effects for CCG and hospital. To isolate the 
excess (cancer- related) hazards of death, the hazards of death 
from other causes were obtained for each patient with cancer 
from English life tables defined for each calendar year in 
Figure 1 Flow chart of data exclusions and hospital assignment after 
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2006–2014 and stratified by single year of age, sex, depri-
vation category and region of residence.22 23 Five- year net 
survival for each CCG and hospital was estimated (based 
on the mean of their posterior distributions) and their vari-
ability across CCGs and hospitals was presented using funnel 
plots.24 Complete model specification details are presented 
in online supplemental appendix A. For this study, informa-
tion on stage at diagnosis was not available for 23% of the 
cancer cases. In order to include all the cases in the analysis, 
we extended the excess hazard model to handle the missing 
stage information by specifying an additional distribution 
for the stage variable that uses information from all the 
covariates included in the main model specification. Addi-
tional analysis performed on complete cases confirmed the 
practical importance and the impact on results of accommo-
dating the missing data structure in the analysis (see results 
in online supplemental appendix A.6, figure A.5). Conven-
tional analyses were completed using Stata V.15,19 whereas 
Bayesian inferences were performed in R software V.3.4.3 
using the JAGS MCMC program accessed via the R package 
‘R2JAGS’.25 26
RESULTS
Data were available on 16 326 patients diagnosed with colon 
cancer between 2006 and 2013 in London, England (see flow 
chart in figure 1). For 15 309 (94%) patients, a hospital of cancer 
care was successfully allocated after the treatment capture algo-
rithm was applied to each cancer record. The 1017 (6%) patients 
for which a hospital of cancer care or diagnosis could not be allo-
cated were not included in further analyses. For 10 869 (71%) of 
the eligible 15 309 patients, the hospital allocated corresponded 
to the hospital where the patient underwent a major surgery for 
colon cancer. For the remaining 4440 (29%) patients, the hospital 
allocated corresponded either to the hospital of diagnosis provi-
sion or palliative care, if no major surgical treatment was recorded.
Table 1 Number of cases (N) and proportion of deaths (%) within the follow- up period by CCG of residence for men and women diagnosed with 
colon cancer in London, 2006–2013
CCG of residence
Men Women
Cases (N) Deaths (%) Cases (N) Deaths (%)
C1: Barking and Dagenham   194   58.8   200 53.5
C2: Barnet   397   48.9   326 48.8
C3: Bexley   308   52.9   270 51.5
C4: Brent   263   44.9   240 49.2
C5: Bromley   414   54.1   428 53.3
C6: Camden   172   51.7   177 46.9
C7: Central London   156   54.5   109 41.3
C8: City and Hackney   187   49.7   176 51.1
C9: Croydon   401   46.9   369 50.7
C10: Ealing   308   50.0   303 47.2
C11: Enfield   308   51.3   323 49.8
C12: Greenwich   246   52.0   223 47.1
C13: Hammersmith and Fulham   154   48.7   160 46.2
C14: Haringey   212   50.9   204 52.9
C15: Harrow   234   42.7   221 44.8
C16: Havering   356   55.3   360 53.6
C17: Hillingdon   310   54.5   298 49.7
C18: Hounslow   215   41.9   206 50.0
C19: Islington   183   52.5   168 44.0
C20: Kingston   173   47.9   197 52.3
C21: Lambeth   240   44.2   245 47.3
C22: Lewisham   221   49.3   215 53.0
C23: Merton   218   48.6   217 50.2
C24: Newham   181   53.6   142 48.6
C25: Redbridge   268   50.4   275 50.9
C26: Richmond   252   43.6   225 46.7
C27: Southwark   218   50.9   214 54.2
C28: Sutton   254   45.7   253 49.0
C29: Tower Hamlets   139   59.7   142 54.9
C30: Waltham Forest   206   51.9   202 58.4
C31: Wandsworth   270   50.4   218 51.8
C32: West London   183   53.5   162 40.1
Total   7841   50.3   7468 50.0
























4 Quaresma M, et al. J Epidemiol Community Health 2021;0:1–10. doi:10.1136/jech-2021-217043
Original research
Individual characteristics of patients with colon cancer by 
CCG and hospital
Tables 1 and 2 show the distribution of cases and deaths for men 
and women by CCG of residence and NHS hospital of cancer 
care, respectively. Of the 15 309 patients included in the anal-
ysis, 7841 (51%) were men and 7468 (49%) were women. The 
number of cancer cases for patients living in a London CCG (and 
treated in a London hospital) within the study period ranged 
between 139 and 414 (median 227) for men and between 109 
and 428 (median 217) for women. The number of cancer cases 
treated in an NHS hospital (and living in London) within the 
study period ranged between 30 and 435 (median 231) for men 
and between 18 and 469 (median 204) for women. Death was 
observed for 7674 (50%) patients over the maximum follow- up 
period of 8.9 years. Deaths ranged between 40% and 60% in 
both men and women for CCG of residence, and between 30% 
and 77% in men and between 38% and 75% in women for 
hospital of care. Survival time was measured from the date of 
diagnosis until the date of death or the date of last follow- up. 
For patients that died, the median survival time was 0.72 year, 
and for censored patients, the median survival time was 4.1 
years. The mean age at diagnosis was 72 years (SD=13.2) for 
men and 74 years (SD=14.4) for women. For both men and 
women, the overall distribution of patients within deprivation 
Table 2 Distribution of colon cancer cases and deaths for men and women, and EP by hospital of cancer care for patients diagnosed with colon 
cancer in London, 2006–2013
Hospital of cancer care
Men Women ‘Internal’ patients ‘External’ patients
Cases (N) Deaths (%) Cases (N) Deaths (%) (%) EP (%) (%) EP (%)
H1: Barnet Hospital 234 47.9 195 50.8 84.2 35.5 15.8 28.0
H2: Central Middlesex Hospital 48 68.7 48 75.0 76.0 56.7 24.0 69.2
H3: Charing Cross Hospital 169 49.7 177 43.5 39.0 36.9 61.0 24.7
H4: Chase Farm Hospital 182 59.3 193 49.2 88.8 35.6 11.2 25.7
H5: Chelsea and Westminster Hospital 180 51.7 180 42.2 40.0 29.0 60.0 33.7
H6: Croydon University Hospital 319 50.8 320 53.4 93.4 32.9 6.6 51.4
H7: Ealing Hospital 181 52.5 153 52.9 93.1 33.0 6.9 40.9
H8: Epsom Hospital 85 29.4 82 37.8 70.7 16.7 29.3 16.3
H9: Guy’s Hospital 88 37.5 90 42.2 32.0 20.8 68.0 25.0
H10: Hammersmith Hospital 72 65.3 68 55.9 30.0 37.1 70.0 27.8
H11: Hillingdon Hospital 245 57.9 247 51.4 95.7 37.0 4.3 61.1
H12: Homerton University Hospital 166 50.0 153 51.6 90.9 31.6 9.1 54.5
H13: King George Hospital 241 58.1 233 55.8 51.9 41.3 48.1 39.8
H14: King’s College Hospital 271 48.7 253 50.2 33.2 34.2 66.8 27.3
H15: Kingston Hospital 354 48.0 355 50.7 45.0 26.8 55.0 24.1
H16: Mount Vernon Hospital 30 76.7 18 61.1 72.9 0.0 27.1 0.0
H17: Newham General Hospital 142 57.7 128 50.8 92.2 39.6 7.8 45.0
H18: North Middlesex Hospital 187 55.6 176 57.4 49.6 34.7 50.4 38.1
H19: Northwick Park Hospital 236 42.4 209 46.9 31.7 39.7 68.3 36.6
H20: Princess Royal University Hospital 372 55.1 368 54.9 89.6 29.1 10.4 33.3
H21: Queen Elizabeth Hospital 339 52.2 277 49.1 58.4 35.3 41.6 34.1
H22: Queen Mary’s Hospital 178 57.9 187 55.6 74.5 24.6 25.5 29.5
H23: Queen’s Hospital 435 55.4 469 54.2 68.8 31.1 31.2 30.2
H24: Royal Free Hospital 235 51.5 217 49.8 33.9 39.4 66.1 27.1
H25: St. George’s Hospital 377 38.2 320 40.0 36.9 34.5 63.1 25.6
H26: St. Helier Hospital 234 58.9 244 59.8 61.9 48.5 38.1 40.8
H27: St. Mark’s Hospital 229 37.1 237 38.8 34.5 16.2 65.5 11.7
H28: St. Mary’s Hospital 265 39.2 227 38.3 25.2 30.2 74.8 22.6
H29: St. Thomas’ Hospital 247 55.1 230 53.9 32.5 40.3 67.5 29.7
H30: The Royal London Hospital 210 52.8 183 51.9 67.2 44.6 32.8 29.3
H31: The Royal Marsden Hospital 99 40.4 99 45.5 9.6 0.0 90.4 19.5
H32: The Whittington Hospital 181 56.3 199 47.2 47.4 40.0 52.6 40.2
H33: University College Hospital 283 40.9 244 39.3 27.9 26.6 72.1 19.9
H34: University Hospital Lewisham 181 47.5 180 49.4 78.4 26.7 21.6 18.8
H35: West Middlesex University Hospital 237 44.7 213 54.4 65.1 44.9 34.9 38.5
H36: Whipps Cross Hospital 309 50.8 296 53.4 61.5 30.1 38.5 21.9
Total 7841 50.3 7468 50.0 58.1 33.8 41.8 28.5
Proportion of patients with colon cancer and of EP according to which CCG the patients live in—within the CCG of each hospital (‘Internal patients’) or coming from other CCGs (‘External 
patients’).
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categories was similar, ranging from 13% of patients in the least 
deprived group to 27% in the most deprived group. Stage at 
diagnosis was missing for 23% of the cases. Among the records 
with observed stage, the overall stage distribution was similar 
for both men and women, with 13% of patients diagnosed with 
stage 1 disease, 34% with stage 2, 34% with stage 3% and 19% 
of patients diagnosed with stage 4. The windrose graphs show 
that the highest proportion of patients from the most deprived 
group came from the North East/East London CCGs and hospi-
tals, reaching over 80% of patients in some areas compared with 
the South West/South London areas where patients from the 
least deprived group are more predominant, although in much 
smaller proportions (figure 2A,B). The distribution of stages 1, 2 
and 3 (grouped into one category) ranged between 50% and 73% 
by CCG of residence and between 37% and 80% by hospital of 
care. The distribution of patients with stage 4 was similar by 
CCG and hospital, ranging between 6% and 26% (figure 2C,D). 
These patterns were similar both for men and women.
Pathways of patients with colon cancer between their CCG of 
residence and hospital of cancer care
The flow maps in figures 3 and 4 display the pathways of 
patients between the CCG of residence and the hospital of 
cancer care for men and women, respectively. Overall, the most 
frequent pathway patients travelled was to the closest hospital 
located within the catchment area of their CCG of residence. 
Similar pathway frequencies were observed for both men and 
women. Three main patterns can be distinguished: (1) For one- 
third of CCGs, namely, Bromley, City and Hackney, Croydon, 
Figure 2 Windrose graphs showing the distribution (%) of male patients diagnosed with colon cancer in London, 2006–2013: (A) least deprived 
versus most deprived category by Clinical Commissioning Group (CCG) of residence; (B) least deprived versus most deprived category by hospital of 
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Greenwich, Havering, Hillingdon, Hounslow, Kingston, 
Newham, Waltham Forest and Tower Hamlets, more than 70% 
of patients travelled to one main hospital closest to their area of 
residence and with lower frequency to other hospitals. In partic-
ular, for patients living in Waltham Forest and Tower Hamlets 
(and Kingston for women), more than 90% travelled to only 
one hospital. (2) The second pattern identified CCGs in which 
patients travelled with similar frequency to two main hospitals 
close to their areas of residence, namely, Barking and Dagenham, 
Bexley, Camden and Islington. (3) For the remaining 17 CCGs, 
patients travelled more frequently up to three or four hospitals, 
travelling further to hospitals outside of their CCG of residence. 
Overall, the patterns displayed in the flow maps clearly define 
areas in London where patients’ travels are more self- contained 
to hospitals located in their neighbouring areas, for example, 
in the North East, East and South East of London. In contrast, 
patients living in the North and South West of London tend to 
access more hospitals outside their area of residence, most of 
them located in central London.
Variations in 5-year cancer survival
Posterior distributions of 5- year net survival were derived for 
each CCG of residence and hospital of cancer care from the 
multivariable excess hazard model, which included, in addition 
to CCG and hospital, age at diagnosis, deprivation and stage (full 
model). Complete model specification and Bayesian inference 
details are presented in online supplemental appendix A.1–A.5. 
From these posterior distributions, funnel plots were created 
by CCG of residence and hospital of care (figures 5 and 6) for 
men and women, respectively. Each funnel plot charts the 5- year 
net survival (posterior mean) against their corresponding preci-
sions. Superimposed on the funnel plots are the 95% and 99.8% 
control limits. The target values (horizontal lines) were taken as 
the mean net survival for London. Net survival values that fall 
within the boundaries of the control limits are noted as consis-
tent with the mean level of net survival in London. Net survival 
values that fall above the boundaries of the control limits exhibit 
more variability (with higher survival) than expected compared 
with the mean level of survival London, and values that fall 
below the boundaries of the control limits exhibit more vari-
ability (with lower survival) than expected compared with the 
mean level of survival in London. Plots were presented strat-
ified by stage at diagnosis because the level of survival is very 
differential between early stages (stages 1, 2 and 3) and late stage 
(stage 4). No variability was observed between CCGs for both 
men and women (figures 5A,C and 6A,C), with all estimates 
almost exactly at the same level as the target line. However, 
large variability was observed between hospitals, although most 
of the estimates were contained within the 99.8% control limits 
in the funnel plots. For stages at diagnosis 1, 2 and 3, hospital- 
specific 5- year net survival ranged between 61% and 77% for 
men (with target 69%) (figure 5B) and between 67% and 76% 
Figure 3 Flow map of London displaying the pathways of patients’ journeys between the area of residence (2013 Clinical Commissioning Groups 
(CCGs)) and the hospital of cancer care for men diagnosed with colon cancer, 2006–2013. Thick black borders define the boundaries for the CCGs as 
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for women (with target 72%) (figure 6B). For stage at diagnosis 
4, the survival estimates ranged between 10% and 28% for men 
(with target 18%) (figure 5D) and between 19% and 32% for 
women (with target 26%) (figure 6D). For comparison of results 
with the full model, three additional excess hazard models were 
fitted by adding covariates successively: model 1, including age 
and CCG; model 2, including age, CCG and deprivation; model 
3, including age, CCG, deprivation and stage. Based on each of 
these models, funnel plots were created by CCG of residence 
to visualise if any survival variability by CCGs was observed 
before the fully adjusted model. For both men and women, the 
5- year net survival varied moderately between CCGs, even after 
adjusting for age at diagnosis, deprivation and stage at diagnosis 
(online supplemental figures 1a–c–4a–c). Such disparities disap-
peared once adjusted for hospital of cancer care, as shown by the 
funnel plots in online supplemental figures 1d–4d.
DISCUSSION
Our results reveal the complexity and multidimensionality of 
the association between the CCG- level colon cancer survival 
and hospital of cancer care for patients diagnosed with colon 
cancer during 2006–2013, who were living and receiving 
care in London, England. Flow maps of patient pathways 
between the CCG of residence and the hospital of cancer care 
revealed that patients travelled more frequently to hospitals 
closest to their area of residence, in particular in the North 
East, East and South East of London, whereas patients living 
in the North and South West of London frequently accessed 
hospitals outside their area of residence. The differential 
frequencies in patient pathways between area of residence 
and hospital of care raise questions regarding the equal 
choice of patients for the best performing hospitals at point 
of referral. Moderate variation in the 5- year net survival 
was observed between CCGs after adjusting for age at diag-
nosis, deprivation and stage at diagnosis. These dispari-
ties disappeared once adjusted for hospital of cancer care, 
while substantial variation between hospitals emerged after 
adjusting for the same patient- level and tumour- level factors. 
Overall, we observed a strong correlation between the net 
survival values estimated in the CCGs and their local hospi-
tals. It is nevertheless crucial for interpretation purposes to 
highlight the weak correlation between some CCGs and their 
local hospitals. In particular, some of the hospitals located 
in CCGs with poorer net survival do not seem to be associ-
ated with lower survival. Further examination of the patient 
flow and the levels of net survival revealed a few points with 
potentially important policy implications. Bromley, Newham, 
Tower Hamlets and Waltham Forest combine (1) some of 
the lowest CCG level 5- year net survival estimates (below 
68%) for patients with colon cancer residing in these London 
CCGs, and (2) some of the highest proportions of patients 
treated within the CCG (above 70% and even above 90% 
Figure 4 Flow map of London displaying the pathways of patients’ journeys between the area of residence (2013 Clinical Commissioning Groups 
(CCGs)) and the hospital of cancer care for women diagnosed with colon cancer, 2006–2013. Thick black borders define the boundaries for the CCGs 
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for Tower Hamlets and Waltham Forest) (figures 3 and 4). 
Hospital- level outcomes, however, differ notably: survival of 
patients with colon cancer managed by the local hospitals 
of Tower Hamlets and Waltham Forest compared well with 
the London average, whereas local hospitals of Bromley and 
Newham presented some of the poorest levels of net survival 
in London (figures 5 and 6). The hospitals of Tower Hamlets 
and Waltham Forest manage large proportions of patients 
with colon cancer coming from other CCGs and those 
‘external patients’ had differential characteristics from those 
who are managed in these hospitals and live within these 
CCGs (‘internal patients’) (table 2). Among the external 
patients, the proportions of EP were around 29% and 22% 
in each local hospital, while the figures were 45% and 30% 
for the internal patients, respectively. These findings suggest 
that the care provided by these hospitals to elective patients 
is as expected, but they also raise questions regarding the 
effective implementation of cancer policies for the popu-
lations within these CCGs, given that high EP propor-
tions commonly reflect longer referral times, poor access 
to specialists, difficulties in accessing diagnostic tests and 
barriers in communication between primary and secondary 
care.27 In addition, the deprivation level is high in most of 
the populations living in these CCGs (ranging between 30% 
and 85% of the population in the most deprived group), 
meaning that these patients, on average, have low awareness 
for cancer symptoms,28 experience barriers to help seeking29 
and have more comorbidities, which complicates both the 
diagnosis30 and the treatment of the cancer. In particular, 
one may wonder whether the shortness of primary care 
consultations does not penalise patients embarrassed or who 
struggle to describe their symptoms and communicate their 
choices. The implementation of the 2- week referral pathway 
does not seem very successful in these areas. The situation 
in Bromley and Newham CCGs strongly contrasts with the 
previous CCGs as their local hospitals presented some of the 
poorest levels of net survival in London with high levels of 
EP (30% and 40%, respectively). This suggests that in addi-
tion to the previously mentioned EP challenges that these 
populations face, the performance of their local hospitals 
and cancer outcomes are very poor even for elective patients, 
raising questions regarding the internal organisation and 
availability of resources these hospitals have for an effective 
cancer management.
To the best of our knowledge, this is the first study to inves-
tigate in- depth variation in cancer survival at both area of resi-
dence and hospital level. The timing of our findings remains 
relevant in the light of both the current COVID-19 pandemic 
and the recent successive regroupings of CCGs. The pandemic 
has led to the temporary suspension of cancer screening services 
and deferred routine diagnostic work, only prioritising urgent 
symptomatic cases for diagnostic intervention. We expect that 
these diagnostic delays will almost surely continue to exacerbate 
the disparities we have observed in our study for the foreseeable 
future. A recent study suggests that as a result of these unprec-
edented diagnostic delays, substantial increases in the number 
Figure 5 Funnel plots of 5- year net survival (mean posterior) for men diagnosed with colon cancer in 2006–2013, London: (A) by Clinical 
Commissioning Group (CCG) of residence for stages at diagnosis 1, 2 and 3; (B) by hospital of cancer care for stages at diagnosis 1, 2 and 3; (C) by 
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of avoidable cancer deaths in England are to be expected, and 
stress the need for urgent policy interventions to mitigate the 
expected impact of the COVID-19 pandemic on patients with 
cancer.31 Our results have shown how the access to cancer care 
can be challenging for populations living in some specific areas 
and it is crucial to monitor how this will be modified by the reor-
ganisation of London CCGs. A close monitoring is even more 
necessary as the new CCG grouping seems to strongly reinforce 
the geographical disparities regarding the sociodemographic and 
the cancer outcomes (see figures 3 and 4). The large size of the 
new CCGs poses the question of how geographical inequalities 
should be monitored and investigated. Furthermore, we advo-
cate caution when interpreting the hospital- specific net survival 
estimates presented in this study, as these hospitals treat more 
patients than the selected cohort of patients with cancer here 
analysed.
In summary, this study demonstrates the importance of 
performing more in- depth investigations into the observed 
disparities in cancer survival using population- based data 
enriched with other relevant health data sources. The results 
presented here pertain only to a small part of England, but 
they reveal a very complex picture of large variation across 
London between access of patients with cancer to specialist 
care and effective delivery of such care. We hypothesise that 
similar patterns exist in the rest of the country, and future 
research should aim to expand a similar analysis to the whole 
of England as a means to inform national policy makers. 
Such an analytical approach would also be very informative 
in other countries with comparable settings. Future work 
should also aim to investigate hospitals with poorer perfor-
mance to understand its causes (including their resources 
What is already known on this subject
 ► Wide geographical inequalities in survival from most cancer 
types have been consistently described in England, with 
similar disparities observed within the capital London, 
despite the existence of free- of- charge care within the 
National Health Service.
What this study adds
 ► Access to cancer care revealed itself challenging for 
populations living in specific areas of London, and our 
results highlight the need to better coordinate primary and 
secondary care sectors in order to improve timely access to 
specialised clinicians and diagnostic tests.
 ► Close monitoring of cancer outcomes remains crucial in 
the light of the most recent reorganisation of Clinical 
Commissioning Groups and the observed exacerbation 
of disparities during the COVID-19 pandemic, not only in 
London but also at national level and for other cancer types.
Figure 6 Funnel plots of 5- year net survival (mean posterior) for women diagnosed with colon cancer in 2006–2013, London: (A) by Clinical 
Commissioning Group (CCG) of residence for stages at diagnosis 1, 2 and 3; (B) by hospital of cancer care for stages at diagnosis 1, 2 and 3; (C) by 
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and organisation), and to examine more in depth (including 
qualitative studies) what determines the choice (or absence 
of choice) of patients for a given hospital in order to suggest 
actions to correct such wide disparities.
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